Kinase Inhibitors

(R,R)-VVD-118313 is the isomer of VVD-118313 ( HY-151385 ). VVD-118313 is a selective JAK1 inhibitor and blocks JAK1-dependent trans-phosphorylation and cytokine signaling. VVD-118313 can be used for research of cancerIn VitroVVD-118313 (compound

(R,R)-VVD-118313 is the isomer of VVD-118313 ( HY-151385 ). VVD-118313 is a selective JAK1 inhibitor and blocks JAK1-dependent trans-phosphorylation and cytokine signaling. VVD-118313 can be used for research of cancerIn VitroVVD-118313 (compound

(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor , and has the potential of reducing the secretion of gastric acid.In Vitro(Rac)-Sograzepide is an antagonist of CCK-B receptor, and has the potential of reducing the secretion

(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor , and has the potential of reducing the secretion of gastric acid.In Vitro(Rac)-Sograzepide is an antagonist of CCK-B receptor, and has the potential of reducing the secretion

(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor , and has the potential of reducing the secretion of gastric acid.In Vitro(Rac)-Sograzepide is an antagonist of CCK-B receptor, and has the potential of reducing the secretion

(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor , and has the potential of reducing the secretion of gastric acid.In Vitro(Rac)-Sograzepide is an antagonist of CCK-B receptor, and has the potential of reducing the secretion

(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor , and has the potential of reducing the secretion of gastric acid.In Vitro(Rac)-Sograzepide is an antagonist of CCK-B receptor, and has the potential of reducing the secretion

A fatty acid amide derived from ricinoleic acid and methyl benzylamine that demonstrates potent growth inhibition of glioma (U251), breast (MCF-7), ovarian (NCI-ADR/RES and OVCAR-3), kidney (786-0), non-small cell lung (NCI-H460), and prostate

A fatty acid amide derived from ricinoleic acid and methyl benzylamine that demonstrates potent growth inhibition of glioma (U251), breast (MCF-7), ovarian (NCI-ADR/RES and OVCAR-3), kidney (786-0), non-small cell lung (NCI-H460), and prostate

A fatty acid amide derived from ricinoleic acid and methyl benzylamine that demonstrates potent growth inhibition of glioma (U251), breast (MCF-7), ovarian (NCI-ADR/RES and OVCAR-3), kidney (786-0), non-small cell lung (NCI-H460), and prostate

A fatty acid amide derived from ricinoleic acid and methyl benzylamine that demonstrates potent growth inhibition of glioma (U251), breast (MCF-7), ovarian (NCI-ADR/RES and OVCAR-3), kidney (786-0), non-small cell lung (NCI-H460), and prostate

Biochem/physiol Actions (S)-CPP is an inhibitor of branched-chain &#945:-ketoacid dehydrogenase complex (BCKDC) kinase, also know as BDK, or keto acid dehydrogenase kinase. BDK is a negative regulator of BCKDC activity.